Актуальная стратегия лечения подагрического артрита
https://doi.org/10.14412/1996-7012-2018-3-70-75
Аннотация
Фебуксостат – непуриновый селективный ингибитор изоформ ксантиноксидоредуктазы (КОР), действие которого направлено на снижение уровня мочевой кислоты в сыворотке крови. Фебуксостат – более мощный ингибитор КОР, чем аллопуринол, что подтверждается достижением целевого уровня МК при лечении фебуксостатом чаще, чем при приеме аллопуринола, особенно у пациентов с высокой концентрацией уратов в сыворотке крови. Фармакокинетические свойства фебуксостата не зависят от почечного клиренса, что отличает его от аллопуринола и может быть преимуществом для пациентов с хроническими заболеваниями почек. В ряде исследований проводится дальнейшая оценка безопасности фебуксостата для сердечно-сосудистой системы и его возможного позитивного действия на сохранение функции почек. Важным является и то, что у пожилых пациентов не требуется коррекции дозы фебуксоcтата.
Об авторах
М. С. Петрова
ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава России
Россия
Россия
Марианна Семеновна Петрова
191015, Санкт-Петербург, ул. Кирочная, 41
М. М. Мусийчук
ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава России
Россия
Россия
191015, Санкт-Петербург, ул. Кирочная, 41
В. И. Мазуров
ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава России
Россия
Россия
191015, Санкт-Петербург, ул. Кирочная, 41
Литература
1. Smith EU, Diaz-Torne C, Perez-Ruiz F, et al. Epidemiology of gout: an update. Best Pract Res Clin Rheumatol. 2010 Dec;24(6): 811-27. doi: 10.1016/j.berh.2010.10.004.
2. Kuo CF, Grainge MJ, Zhang W, et al. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015 Nov;11(11):649-62. doi: 10.1038/nrrheum.2015.91. Epub 2015 Jul 7.
3. Hak AE, Curhan GC, Grodstein F, et al. Menopause, postmenopausal hormone use and risk of incident gout. Ann Rheum Dis. 2010 Jul;69(7):1305-9. doi: 10.1136/ard.2009.109884. Epub 2009 Jul 9.
4. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011 Oct;63(10):3136-41. doi: 10.1002/art.30520.
5. Shiozawa A, Szabo SM, Bolzani A, et al. Serum Uric Acid and the Risk of Incident and Recurrent Gout: A Systematic Review. J Rheumatol. 2017 Mar;44(3):388-396. doi: 10.3899/jrheum.160452. Epub 2017 Feb 1.
6. Mendez Landa CE. Renal Effects of Hyperuricemia. Contrib Nephrol. 2018;192:8-16. doi: 10.1159/000484273. Epub 2018 Jan 23.
7. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017 Jan;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707. Epub 2016 Jul 25.
8. Zgaga L, Theodoratou E, Kyle J, et al. The association of dietary intake of purinerich vegetables, sugar-sweetened beverages and dairy with plasma urate, in a crosssectional study. PLoS One. 2012;7(6):e38123. doi: 10.1371/journal.pone.0038123. Epub 2012 Jun 6.
9. Dalbeth N, Lauterio TJ, Wolfe HR. Mechanism of action of colchicine in the treatment of gout. Clin Ther. 2014 Oct 1;36(10):1465-79. doi: 10.1016/j.clinthera.2014.07.017. Epub 2014 Aug 21.
10. Rothenbacher D, Kleiner A, Koenig W, et al. Relationship between inflammatory cytokines and uric acid levels with adverse cardiovascular outcomes in patients with stable coronary heart disease. PLoS One. 2012;7(9): e45907. doi: 10.1371/journal.pone.0045907. Epub 2012 Sep 21.
11. Chen H, Mosley TH, Alonso A, et al. Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol. 2009 May 1;169(9): 1064-9. doi: 10.1093/aje/kwp033. Epub 2009 Mar 18.
12. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006 Oct;65(10):1312-24. Epub 2006 May 17.
13. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012 Oct;64(10):144761. doi: 10.1002/acr.21773.
14. Richette P, Bardin T. Gout. Lancet. 2010 Jan 23;375(9711):318-28. doi: 10.1016/S01406736(09)60883-7. Epub 2009 Aug 17.
15. Seth R, Kydd AS, Buchbinder R, et al. Allopurinol for chronic gout. Cochrane Database Syst Rev. 2014 Oct 14;(10): CD006077. doi: 10.1002/14651858.CD006077.pub3.
16. Diaz-Torne C, Perez-Herrero N, PerezRuiz F. New medications in development for the treatment of hyperuricemia of gout. Curr Opin Rheumatol. 2015 Mar;27(2):164-9. doi: 10.1097/BOR.0000000000000146.
17. Kydd AS, Seth R, Buchbinder R, et al. Uricosuric medications for chronic gout. Cochrane Database Syst Rev. 2014 Nov 14;(11): CD010457. doi: 10.1002/14651858.CD010457.pub2.
18. Castrejon I, Toledano E, Rosario MP, et al. Safety of allopurinol compared with other uratelowering drugs in patients with gout: a systematic review and meta-analysis. Rheumatol Int. 2015 Jul;35(7):1127-37. doi: 10.1007/s00296-014-3189-6. Epub 2014 Dec 18.
19. Adenuric. European Medicines Agency. Human medicines. Authorisation details. United Kingdom, 2015. [Last accessed 19 August 2015]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Summary _for_the_public/human/000777/WC500021813.pdf
20. Uloric. U. S. Food and Drug Administration. Drug approval package. United States; 2009. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021856s000toc.cfm
21. Uloric. Full prescribing information. U. S. Food and Drug Administration. United States; 2012.
22. Mukoyoshi M, Nishimura S, Hoshide S, et al. In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. Xenobiotica. 2008 May;38(5):496-510. doi: 10.1080/00498250801956350.
23. Takano Y, Hase-Aoki K, Horiuchi H, et al. Selectivity of febuxostat, a novel nonpurine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci. 2005 Mar 4;76(16): 1835-47. Epub 2005 Jan 18.
24. Khosravan R, Grabowski BA, Wu JT, et al. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. Clin Pharmacokinet. 2006;45(8):821-41.
25. Khosravan R, Grabowski B, Wu JT, et al. Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects. Br J Clin Pharmacol. 2008 Mar;65(3):355-63. Epub 2007 Oct 22.
26. Komoriya K, Hoshide S, Takeda K, et al. Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia. Nucleosides Nucleotides Nucleic Acids. 2004 Oct; 23(8-9):1119-22.
27. Mayer MD, Khosravan R, Vernillet L, et al. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther. 2005 Jan-Feb;12(1):22-34.
28. Adenuric. Summary of product characteristics. European Medicines Agency. United Kingdom; 2015.
29. Perez-Ruiz F, Punzi L. Hyperuricemia and tissue monourate deposits: prospective therapeutic considerations. Eur Rev Med Pharmacol Sci. 2015;19(9):1549-52.
30. Adenuric. Public Summary Document. Pharmaceutical Benefits Advisory Committee. Australia; 2015.
31. Japanese Society of Gout and Nucleic Acid Metabolism. Digest of Guideline for the Management of Hyperuricemia and Gout: second edition. Gout and Nucleic Acid Metabolism. 2010;34(1):109-44.
32. Richette P, Frazier A, Bardin T. Impact of anti-inflammatory therapies, xanthine oxidase inhibitors and other urate-lowering therapies on cardiovascular diseases in gout. Curr Opin Rheumatol. 2015 Mar;27(2):170-4. doi: 10.1097/BOR.0000000000000149.
33. Sanchez-Lozada LG, Tapia E, Soto V, et al. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transplant. 2008 Apr;23(4):1179-85. Epub 2007 Nov 29.
34. Whelton A, Macdonald PA, Zhao L, et al. Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol. 2011 Jan;17(1):7-13. doi: 10.1097/RHU.0b013e318204aab4.
35. Sircar D, Chatterjee S, Waikhom R, et al. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, PlaceboControlled Trial. Am J Kidney Dis. 2015 Dec;66(6):945-50. doi: 10.1053/j.ajkd.2015.05.017. Epub 2015 Jul 30.
36. Zhang M, DI X, Xu L, et al. Pharmacokinetics and pharmacodynamics of febuxostat under fasting conditions in healthy individuals. Exp Ther Med. 2014 Feb;7(2):393-396. Epub 2013 Nov 19.
37. Hoshide S, Takahashi Y, Ishikawa T, et al. PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1117-8.
38. Khosravan R, Grabowski BA, Mayer MD, et al. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol. 2006 Jan;46(1):88-102.
39. Schumacher HR, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008 Nov 15;59(11):1540-8. doi: 10.1002/art.24209.
Рецензия
Для цитирования:
Петрова МС, Мусийчук ММ, Мазуров ВИ. Актуальная стратегия лечения подагрического артрита. Современная ревматология. 2018;12(3):70-75. https://doi.org/10.14412/1996-7012-2018-3-70-75
For citation:
Petrova MS, Musiychuk МM, Mazurov VI. The current treatment strategy for gouty arthritis. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2018;12(3):70-75. (In Russ.) https://doi.org/10.14412/1996-7012-2018-3-70-75
Просмотров:
988
Послать статью по эл. почте 